Market News How it works Learn FAQ
| TGL 0.2897 30.79% | SRTM 0.6164 43.25% | NU 11.845 -21.87% | GCDT 0.1604 -8.92% | EWZ 31.98 -24.91% | NWGL 0.0808 -1.46% | SHFS 0.1254 -5.29% | RBNE 0.183 -3.68% | CLRO 4.2705 31.40% | SPRC 1.635 50.00% | SOXL 87.29 4.46% | BBD 2.9088 -28.53% | VBIO 0.785 -16.49% | RENT 2.85 23.91% | ITUB 7.63 -21.10% | PBR 21.675 -17.14% | SOXS 50.2 -4.31% | TSLL 10.68 9.43% | SPCX 147.12 -0.25% | XP 14.42 -52.58% | XXII 0.1032 -47.80% | GPUS 0.1583 -6.28% | WFF 0.0741 -7.38% | KORU 10.59 0.09% | CRWV 52.0841 -3.97% | IREN 24.13 -3.11% | STNE 7.83 -31.79% | SQQQ 39.02 -1.66% | PRSO 0.35 -7.51% | NOK 8.44 3.69% | INTR 4.751 -33.92% | MYND 0.2219 -7.54% | TQQQ 67.37 1.63% | INTC 88.11 1.32% | VALE 12.27 -1.05% | NVDA 214.88 1.86% | TSLA 389.99 4.77% | VZ 43.45 -2.71% | IBIT 44.9769 -2.14% | WORX 2.2101 0.92% | YMAT 2.25 9.76% | AZTR 0.9102 1,173.01% | JBLU 2.4312 -7.38% | STLA 4.105 1.11% | WULF 11.36 0.35% | T 21.075 0.69% | IRE 2.9 -6.15% | PAGS 8.6 -24.83% | META 631.35 -1.75% | NBIS 151.07 -4.83%
DADay One Biopharmaceuticals, Inc. logo

Day One Biopharmaceuticals, Inc. (DAWN)

NASDAQ Global Select · Currency in USD
$21.53 ▲ +0.00 (+0.00%)
As of Apr 24, 9:30 AM ET. Market open.

Summary

Previous Close
$21.53
Open
$21.53
Day's Range
$21.53 – $21.53
52 Week Range
$5.64 – $21.53
Volume
0
Avg. Volume
4,006,348
Market Cap
$2.22B
Beta (5Y Monthly)
-1.75
PE Ratio (TTM)
--
EPS (TTM)
-$0.69
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$31.30

Profile: Day One Biopharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
181
CEO
Jeremy Bender

Operating as a clinical-stage biopharmaceutical entity, Day One Biopharmaceuticals, Inc. is dedicated to discovering and commercializing precise therapeutic options for individuals battling genetically defined cancers. A key asset is DAY101, an orally administered, brain-permeable type II pan-rapidly accelerated fibrosarcoma kinase inhibitor, currently undergoing Phase II clinical trials for young patients experiencing recurrent or worsening low-grade glioma. Additionally, the company is advancing Pimasertib, an oral small molecule designed to inhibit mitogen-activated protein kinase kinases 1 and 2.

Earnings

DateEst.Actual
May 5, 2026-$0.31-$0.35Miss
Feb 24, 2026-$0.17-$0.20Miss
Nov 4, 2025-$0.28-$0.19Beat
Aug 5, 2025-$0.35-$0.29Beat
May 6, 2025-$0.46-$0.35Beat
Feb 25, 2025-$0.35-$0.69Miss

Analyst view

Consensus price target
$31.30 ▲ +45.4%
Range $21.50 – $45.00
Rating: Buy
Buy 50% · Hold 50% · Sell 0%

Get free alerts on DAWN and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.